Jim Xiangxin Shen

Jim Xiangxin Shen

Auto-generated profile, based on publicly available information

Jim Xiangxin Shen

Research & Development, Bristol-Myers Squibb, Princeton, NJ08543, USA

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2005 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
JSJim X. Shen
Jim X. Shen
RMRichard J. Motyka
Richard J. Motyka
JRJerry P. Roach
Jerry P. Roach
RHRoger N. Hayes
Roger N. Hayes

8 August 2014 in Analytical Chemistry
Verified
Journal Article
Closed access
GLGuowen Liu
Guowen Liu
YZYue Zhao
Yue Zhao
AAAida Angeles
Aida Angeles
LHLora L. Hamuro
Lora L. Hamuro
MAMark E. Arnold
Mark E. Arnold
JSJim X. Shen
Jim X. Shen

1 January 2007 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
JSJim X. Shen
Jim X. Shen
GKGopal Krishna
Gopal Krishna
RHRoger N. Hayes
Roger N. Hayes

1 August 2009 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
JCJennifer M. Cunliffe
Jennifer M. Cunliffe
CNCarl F. Noren
Carl F. Noren
RHRoger N. Hayes
Roger N. Hayes
RCRobert P. Clement
Robert P. Clement
JSJim X. Shen
Jim X. Shen

1 February 2006 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
JSJim X. Shen
Jim X. Shen
HWHaiping Wang
Haiping Wang
STSamy Tadros
Samy Tadros
RHRoger N. Hayes
Roger N. Hayes

1 August 2014 in Bioanalysis
Verified
Journal Article
Closed access
JPJanice Pursley
Janice Pursley
JSJim X Shen
Jim X Shen
ASAlan Schuster
Alan Schuster
ODOanh T Dang
Oanh T Dang
JLJim Lehman
Jim Lehman
MAMark E Arnold
Mark E Arnold
Apixaban (BMS-562247) (Eliquis(®)) is a novel, orally active, selective, direct, reversible inhibitor of the coagulation factor Xa (FXa). A sensitive and reliable method was developed and validated for the measurement of apixaban (BMS-562247) and its major circulating metabolite (BMS-730823) in human citrated plasma for use in clinical testing. A 0.100 ml portion of citrated plasma sample was extracted and analyzed by LC-MS/MS. Run times were approximately 3 min. The lower limit of quantification (LLOQ) was 1.00 ng/ml for BMS-562247 and 5.00 ng/ml for BMS-730823. Intra- and inter-assay precision values for replicate QC control samples were within ≤5.36% for both analytes (≤7.52% at the LLOQ). The accuracy for both analytes was within ±9.00%. The method was demonstrated to be sensitive, selective and robust, and was successfully used to support clinical studies.